{"protocolSection":{"identificationModule":{"nctId":"NCT05636306","orgStudyIdInfo":{"id":"NoNO42-01"},"organization":{"fullName":"NoNO Inc.","class":"INDUSTRY"},"briefTitle":"A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults","officialTitle":"A Phase 1, Randomized, Placebo Controlled, Double-Blind, Single Dose Escalation Study of NoNO-42 in Healthy Adults"},"statusModule":{"statusVerifiedDate":"2023-09","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-11-22","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-10-10","type":"ESTIMATED"},"completionDateStruct":{"date":"2023-10-10","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-11-22","studyFirstSubmitQcDate":"2022-12-01","studyFirstPostDateStruct":{"date":"2022-12-05","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-09-08","lastUpdatePostDateStruct":{"date":"2023-09-11","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"NoNO Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics of a single ascending intravenous dose of NoNO-42 administered to healthy adults.\n\nParticipants will be administered a single intravenous dose of NoNO-42 or placebo.\n\nParticipants will be confined for 24 hours post dose with a follow-up visit at Day 4 and Day 28."},"conditionsModule":{"conditions":["First-In-Human Study to Evaluate Safety of a New Drug Intended for Treatment of Acute Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"OTHER","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":44,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"NoNO-42","type":"EXPERIMENTAL","description":"A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute","interventionNames":["Drug: NoNO-42"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"NoNO-42","description":"A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute","armGroupLabels":["NoNO-42"]},{"type":"DRUG","name":"Placebo","description":"A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Frequency of AEs, abnormal laboratory findings and abnormal vital signs","description":"* Incidence, severity, and causal relationship of AEs.\n* Incidence of abnormal laboratory findings, including histamine.\n* Incidence of abnormal vital signs (blood pressure, heart rate, temperature) and electrocardiogram (ECG) parameters","timeFrame":"28 days"}],"secondaryOutcomes":[{"measure":"Pharmacokinetics of NoNO-42 following administration of a single ascending IV dose","timeFrame":"24 hours"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures, clinic visits, blood draws, and availability for the duration of the study\n* Healthy adult male or female aged 18 to 60 years old.\n* Body mass index (BMI) within 18.5 kg/m2 to 30.0 kg/m2, inclusively\n* Body weight less than or equal to 120 kg\n* Good bilateral venous access sufficient for IV infusions as judged by the investigator or designee\n* Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on the physical examination (including vital signs) and/or ECG, as determined by an investigator\n\nExclusion Criteria:\n\n* Female who is lactating or pregnant\n* History of significant hypersensitivity to NoNO-42 or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs\n* Presence or history of significant gastrointestinal, liver or kidney disease, or surgery that may affect drug bioavailability\n* History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic, renal, hepatic, or dermatologic disease\n* Presence of clinically significant ECG abnormalities, or any QT interval abnormalities, at the screening visit, as defined by medical judgment\n* Immunization with a COVID-19 vaccine in the 14 days prior to the first study drug administration or plans for vaccination\n* Blood pressure below 100 mmHg systolic and 60 mmHg diastolic, and any upper limit is deemed clinically significant by the investigator\n* Estimated glomerular filtration rate (eGFR) of \\<60 mL/min.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Michael Tymianski, MD PhD","role":"CONTACT","phone":"4165831687","email":"mtymianski@nonoinc.ca"},{"name":"Kathy Heard, MSc","role":"CONTACT","phone":"4165831687","email":"kheard@nonoinc.ca"}],"locations":[{"facility":"Altasciences Company Inc.","status":"RECRUITING","city":"Mount Royal","state":"Quebec","zip":"H3P 3P1","country":"Canada","contacts":[{"name":"Eric Sicard, MD","role":"CONTACT","phone":"(514) 858-6077","email":"esicard@altasciences.com"}],"geoPoint":{"lat":45.51675,"lon":-73.64918}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Acute Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}